Company Analysis
Sign in

UroGen Pharma Ltd. (URGN)

Nasdaq: URGN · Pharmaceutical Preparations · Ra'Anana, IL · filing with the SEC since 2016
Full chart Alerts Compare
Grade5.2
◀ Past 5.1● Present 5.5▶ Future 4.8
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$110M+21.4%
Net income-$153M-21.0%
Earnings per share$-3.19-7.8%
Operating cash flow-$162M-67.9%
Cash$111M-35.6%
Debt$122M+0.4%
Shareholders’ equity-$105M-1098.2%
Shares, diluted48.1M+12.2%
Return on equityn/a
The recordfrom its filings
Filings in 202653
Newest filingNov 4 · S-8
Annual reportMar 2, 2026
Quarterly reportNov 4, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$4.8M
Insider buys, 12 months$0.00
Patents granted14
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Revenue $250MNet income -$65.8MCash from operations -$132Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 4, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton URGN · research, not advice